PROCEPT BioRobotics Corporation (PRCT) Stock Price & Analysis
PROCEPT BioRobotics Corporation (PRCT) closed at USD 18.15 on Thursday, October 15, 2026, up 3.66% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.51; the Oct 15, 2026 session ranged USD 17.58–18.23 on volume of 1,247,815 shares. Market capitalization is $1.03B, with a 52-week range of USD 16.67–38.11 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PRCT.md
Key facts (PRCT)
- Analysts: Hold (mean 2.67 on a 1–5 scale) (15 analysts), mean target USD 22.25 (range 16–30).
- Total return with dividends: 1Y -46.5% vs S&P 500 +18.1%; 5Y -58.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.39, revenue estimate $101M.
Analysts (PRCT)
Consensus Hold (mean 2.67 on a 1–5 scale), 15 analysts; mean target USD 22.25 (low 16, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Overweight | $30 |
| 2026-08-05 | TD Cowen | Target lowered | Buy | $34 → $28 |
| 2026-08-05 | Piper Sandler | Target lowered | Overweight | $35 → $25 |
| 2026-08-05 | Evercore ISI Group | Target lowered | Outperform | $30 → $23 |
| 2026-08-05 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-07-06 | Truist Securities | Downgrade | Buy → Hold | $30 → $25 |
| 2026-06-24 | Evercore ISI Group | Initiated | Outperform | $30 |
Total return (dividends reinvested) (PRCT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -46.5% | -58.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -46.6% | -16.0% |
| Volatility (annualized) | 64.7% | 56.4% |
| Max drawdown | -54.8% (Oct 2025→Jul 2026) | -83.2% (Nov 2024→Jul 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 18.15 |
|---|---|
| Change | ▲ 3.66% (up) |
| Previous Close | USD 17.51 |
| Open | USD 17.58 |
| Day Range | USD 17.58 – 18.23 |
| 52-Week Range | USD 16.67 – 38.11 |
| Volume | 1,247,815 shares |
| Market Cap | $1.03B |
| Exchange | NGM |
Technical Analysis (PRCT)
Nexqual's technical model rates PRCT "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.56 (neutral) |
| vs SMA50 | Below (USD 19.85) |
| MACD | -0.39 (negative) |
Analyst Ratings (PRCT)
Wall Street analysts rate PRCT "Hold" based on 15 analysts, with a mean price target of USD 22.25 (range USD 16–30), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 22.25 |
| High Target | USD 30 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 5 / 9 / 1 |
Earnings (PRCT)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $100.71M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.47 vs est -0.45 ▼ miss |
| 2026-03-31 | USD -0.56 vs est -0.57 ▲ beat |
| 2025-12-31 | USD -0.53 vs est -0.32 ▼ miss |
| 2025-09-30 | USD -0.38 vs est -0.42 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (PRCT)
| Total Revenue | $337.34M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +19.30% |
| Gross Margin | +63.36% |
| Operating Margin | -32.05% |
| Profit Margin | -32.53% |
| ROE | -30.24% |
| Debt / Equity | 0.23 |
| Current Ratio | 6.55 |
| Total Cash | $227.91M |
| Total Debt | $77.50M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (PRCT)
Nexqual rates PROCEPT BioRobotics Corporation's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +37% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 63%, operating -32% |
| Balance Sheet | Strong — $228M cash vs $78M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$74M (TTM) |
| Efficiency | Critical — ROE -30%, ROA -14.8% |
Ownership (PRCT)
| Insider Ownership | +3.49% |
|---|---|
| Institutional Ownership | +97.74% |
| Shares Outstanding | 56.92M |
| Float | 55.81M |
| Short % of Float | +13.35% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (PRCT)
PROCEPT BioRobotics Corporation is led by Larry L. Wood (age 59), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | Larry L. Wood (age 59) |
|---|---|
| Executive VP & CFO | Kevin Waters (age 48) |
| Executive Vice President of Operations | Christofer Christoforou (age 55) |
| Executive VP & CTO | Barry Templin |
| Vice President of Investor Relations | Matthew James Bacso C.F.A. |
Major Backers & Investors (PRCT)
Notable institutional backers of PROCEPT BioRobotics Corporation include T. Rowe Price, BNP Paribas Asset Management Holding S.A., FMR, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 9.22% |
| BNP Paribas Asset Management Holding S.A. | 4.93% |
| FMR, LLC | 2.52% |
| Price (T.Rowe) Associates Inc | 2.33% |
| Wellington Management | 2.22% |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.23% |
| BlackRock | 11.01% |
| State Street | 2.82% |
| Geode Capital | 2.59% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt